Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation.

2.50
Hdl Handle:
http://hdl.handle.net/10541/99779
Title:
Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation.
Authors:
Linch, D C; Scarffe, J Howard; Proctor, S; Chopra, R; Taylor, P R; Morgenstern, Godfrey R; Cunningham, D; Burnett, A K; Cawley, J C; Franklin, I M
Abstract:
A multicentre, randomised vehicle-controlled single-blind dose ranging trial of intravenous recombinant granulocyte colony-stimulating factor (rhuG-CSF) administration after BMT has been performed in 121 patients with non-myeloid malignancies. All the doses of rhuG-CSF used (2-20 micrograms/kg/day) resulted in significant acceleration of neutrophil recovery, and a dose-response effect was apparent (p < 0.05). At the 20 micrograms/kg/day dose of rhuG-CSF the median time taken to achieve a neutrophil count of > 0.5 x 10(9)/1 was reduced from 19 to 13 days (p < 0.001) and the time to achieve a neutrophil count > 1.0 x 10(9)/1 on the first of 3 consecutive days, from 26 to 14 days (p < 0.001). There was a trend to less antibiotic use in the rhuG-CSF recipients and the median time in hospital was markedly reduced by 11-15 days (p < 0.01). There was no toxicity in this study attributable to rhuG-CSF.
Affiliation:
University College Hospital, London, UK.
Citation:
Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. 1993, 11 (4):307-11 Bone Marrow Transplant.
Journal:
Bone Marrow Transplantation
Issue Date:
Apr-1993
URI:
http://hdl.handle.net/10541/99779
PubMed ID:
7683552
Type:
Article
Language:
en
ISSN:
0268-3369
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorLinch, D Cen
dc.contributor.authorScarffe, J Howarden
dc.contributor.authorProctor, Sen
dc.contributor.authorChopra, Ren
dc.contributor.authorTaylor, P Ren
dc.contributor.authorMorgenstern, Godfrey Ren
dc.contributor.authorCunningham, Den
dc.contributor.authorBurnett, A Ken
dc.contributor.authorCawley, J Cen
dc.contributor.authorFranklin, I Men
dc.date.accessioned2010-05-25T11:55:48Z-
dc.date.available2010-05-25T11:55:48Z-
dc.date.issued1993-04-
dc.identifier.citationRandomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. 1993, 11 (4):307-11 Bone Marrow Transplant.en
dc.identifier.issn0268-3369-
dc.identifier.pmid7683552-
dc.identifier.urihttp://hdl.handle.net/10541/99779-
dc.description.abstractA multicentre, randomised vehicle-controlled single-blind dose ranging trial of intravenous recombinant granulocyte colony-stimulating factor (rhuG-CSF) administration after BMT has been performed in 121 patients with non-myeloid malignancies. All the doses of rhuG-CSF used (2-20 micrograms/kg/day) resulted in significant acceleration of neutrophil recovery, and a dose-response effect was apparent (p < 0.05). At the 20 micrograms/kg/day dose of rhuG-CSF the median time taken to achieve a neutrophil count of > 0.5 x 10(9)/1 was reduced from 19 to 13 days (p < 0.001) and the time to achieve a neutrophil count > 1.0 x 10(9)/1 on the first of 3 consecutive days, from 26 to 14 days (p < 0.001). There was a trend to less antibiotic use in the rhuG-CSF recipients and the median time in hospital was markedly reduced by 11-15 days (p < 0.01). There was no toxicity in this study attributable to rhuG-CSF.en
dc.language.isoenen
dc.subjectCanceren
dc.subjectHaematopoiesisen
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshBlood Transfusion-
dc.subject.meshBone Marrow Transplantation-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshFever-
dc.subject.meshGlycosylation-
dc.subject.meshGranulocyte Colony-Stimulating Factor-
dc.subject.meshHematopoiesis-
dc.subject.meshHumans-
dc.subject.meshImmunologic Factors-
dc.subject.meshIncidence-
dc.subject.meshInfusions, Intravenous-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasms-
dc.subject.meshNeutropenia-
dc.subject.meshRecombinant Proteins-
dc.subject.meshSepsis-
dc.subject.meshSingle-Blind Method-
dc.subject.meshStomatitis-
dc.subject.meshVehicles-
dc.titleRandomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation.en
dc.typeArticleen
dc.contributor.departmentUniversity College Hospital, London, UK.en
dc.identifier.journalBone Marrow Transplantationen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.